Announcement PDF Atomo Diagnostics Limited ACN 142 925 684 Level 1, 3-5 George St Leichhardt NSW 2040 ASX Announcement 30 January 2026 Atomo Secures a Significant Order for HIV Self-Test SYDNEY, 30 January, Australia, 2026 - Atomo Diagnostics Limited (ASX:AT1) (Atomo) is pleased to announce securing a purchase order for A$416,000 worth of HIV Self-Tests for supply to an African country. Manufactured byAtomo under the Mylan brand and paid for with funding from the Global Fund. Atomo considers the revenue from this order to be material. This is the second order for HIV Self-Tests paid for by the Global Fund since the start of 2026, with the company announcing a prior order earlier (AT1:ASX Announcement dated 15th January 2026, Atomo Secures a Significant Order for HIV Self-Test). Atomo’s Managing Director John Kelly said, “We are delighted to see increasing demand for our HIV Self-Test globally, and look forward to continuing to grow our HIV business over the coming year.” For more information, please contact: John Kelly Atomo Diagnostics john.kelly@atomodiagnostics.com Phone: +61 401 922 279 This announcement was authorised by the Managing Director & CEO. Atomo Diagnostics Limited ACN 142 925 684 Level 1, 3-5 George St Leichhardt NSW 2040 About Atomo Atomo is an Australian headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. Atomo’s unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including HIV, viral vs bacterial differentiation and the early detection of pregnancy. See more at www.atomodiagnostics.com